Latest filing published 12 Jun 2025 for Atara Biotherapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Pascal Touchon in Atara Biotherapeutics, Inc., where the filings describe the role as chief executive. Between 18 May 2021 and 10 June 2025, the trades on record add up to 21 filings.
The open-market record consists of 17 sales worth €1.1M, with no purchase. Other entries cover 4 share grants.
On 12 June 2025 came the latest disclosure, a share grant in Atara Biotherapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations